Cargando…
Antifibrinolytics in a rural trauma state: assessing the opportunities
BACKGROUND: Tranexamic acid (TXA) has demonstrated improved mortality among trauma patients. However, recent evidence from urban US trauma centers has failed to show a benefit among the civilian population. TXA in rural states has not been evaluated. This study aimed to evaluate the current use of T...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5877915/ https://www.ncbi.nlm.nih.gov/pubmed/29766102 http://dx.doi.org/10.1136/tsaco-2017-000107 |
_version_ | 1783310790417186816 |
---|---|
author | Bardes, James M Palmer, Amanda Con, Jorge Wilson, Alison Schaefer, Gregory |
author_facet | Bardes, James M Palmer, Amanda Con, Jorge Wilson, Alison Schaefer, Gregory |
author_sort | Bardes, James M |
collection | PubMed |
description | BACKGROUND: Tranexamic acid (TXA) has demonstrated improved mortality among trauma patients. However, recent evidence from urban US trauma centers has failed to show a benefit among the civilian population. TXA in rural states has not been evaluated. This study aimed to evaluate the current use of TXA in the rural trauma population. METHODS: A retrospective observational review at a level 1 trauma center based in a rural environment. Records were reviewed for TXA indications. TXA indication was defined as: systolic blood pressure <90 mm Hg, blood transfusion, or with a clinical concern for ongoing bleeding. Patients were ineligible if the time since injury was >3 hours. RESULTS: 400 patients were evaluated. 54% of patients met indications for TXA. 14% of these received TXA. 30.4% with an indication for TXA were ineligible due to arrival beyond 3 hours from time of injury. 135 patients arrived as transfers, 265 from the scene. There was no difference in TXA indications between scene and transfers (73 vs 144, p=1). Transfers were more likely to arrive beyond the 3-hour window (59 vs 7, p=0.001). Mortality for patients treated with TXA was 12.5%. This was not significantly different from patients not treated with TXA (19%). DISCUSSION: In a rural system, long transfers exclude most patients from treatment with TXA. A multicenter rural trauma center study will be needed to better define the optimal use of TXA in rural populations. LEVEL OF EVIDENCE: Level IV data: therapeutic/care management. |
format | Online Article Text |
id | pubmed-5877915 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-58779152018-05-14 Antifibrinolytics in a rural trauma state: assessing the opportunities Bardes, James M Palmer, Amanda Con, Jorge Wilson, Alison Schaefer, Gregory Trauma Surg Acute Care Open Original Article BACKGROUND: Tranexamic acid (TXA) has demonstrated improved mortality among trauma patients. However, recent evidence from urban US trauma centers has failed to show a benefit among the civilian population. TXA in rural states has not been evaluated. This study aimed to evaluate the current use of TXA in the rural trauma population. METHODS: A retrospective observational review at a level 1 trauma center based in a rural environment. Records were reviewed for TXA indications. TXA indication was defined as: systolic blood pressure <90 mm Hg, blood transfusion, or with a clinical concern for ongoing bleeding. Patients were ineligible if the time since injury was >3 hours. RESULTS: 400 patients were evaluated. 54% of patients met indications for TXA. 14% of these received TXA. 30.4% with an indication for TXA were ineligible due to arrival beyond 3 hours from time of injury. 135 patients arrived as transfers, 265 from the scene. There was no difference in TXA indications between scene and transfers (73 vs 144, p=1). Transfers were more likely to arrive beyond the 3-hour window (59 vs 7, p=0.001). Mortality for patients treated with TXA was 12.5%. This was not significantly different from patients not treated with TXA (19%). DISCUSSION: In a rural system, long transfers exclude most patients from treatment with TXA. A multicenter rural trauma center study will be needed to better define the optimal use of TXA in rural populations. LEVEL OF EVIDENCE: Level IV data: therapeutic/care management. BMJ Publishing Group 2017-10-05 /pmc/articles/PMC5877915/ /pubmed/29766102 http://dx.doi.org/10.1136/tsaco-2017-000107 Text en © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted. This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
spellingShingle | Original Article Bardes, James M Palmer, Amanda Con, Jorge Wilson, Alison Schaefer, Gregory Antifibrinolytics in a rural trauma state: assessing the opportunities |
title | Antifibrinolytics in a rural trauma state: assessing the opportunities |
title_full | Antifibrinolytics in a rural trauma state: assessing the opportunities |
title_fullStr | Antifibrinolytics in a rural trauma state: assessing the opportunities |
title_full_unstemmed | Antifibrinolytics in a rural trauma state: assessing the opportunities |
title_short | Antifibrinolytics in a rural trauma state: assessing the opportunities |
title_sort | antifibrinolytics in a rural trauma state: assessing the opportunities |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5877915/ https://www.ncbi.nlm.nih.gov/pubmed/29766102 http://dx.doi.org/10.1136/tsaco-2017-000107 |
work_keys_str_mv | AT bardesjamesm antifibrinolyticsinaruraltraumastateassessingtheopportunities AT palmeramanda antifibrinolyticsinaruraltraumastateassessingtheopportunities AT conjorge antifibrinolyticsinaruraltraumastateassessingtheopportunities AT wilsonalison antifibrinolyticsinaruraltraumastateassessingtheopportunities AT schaefergregory antifibrinolyticsinaruraltraumastateassessingtheopportunities |